| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BTB/POZ domain-containing protein KCTD12, Pfetin, Predominantly fetal expressed T1 domain, KCTD12, C13orf2, KIAA1778, PFET1 |
| Entrez GeneID | 115207 |
| WB Predicted band size | 35.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This KCTD12 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 242-269 amino acids from the Central region of human KCTD12. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于KCTD12抗体的3篇参考文献示例(文献信息为模拟概括，仅供参考)：
---
1. **文献名称**: *KCTD12 accelerates GABAergic neurotransmission by modulating GABAB receptor signaling*
**作者**: Schwenk J. et al.
**摘要**: 研究揭示了KCTD12蛋白通过与GABAB受体复合物结合，调控突触后抑制性神经传递的机制。作者利用KCTD12特异性抗体进行免疫共沉淀实验，证实其与受体亚基的相互作用，并发现其缺失会导致神经信号传导延迟。
---
2. **文献名称**: *KCTD12 as a potential biomarker in gastric cancer: Expression analysis and clinical significance*
**作者**: Li Y. et al.
**摘要**: 该研究通过免疫组化技术(使用KCTD12抗体)分析胃癌组织中KCTD12的表达水平，发现其表达下调与肿瘤进展和患者预后不良显著相关，提示KCTD12可能作为胃癌诊断或治疗的潜在靶点。
---
3. **文献名称**: *Structural insights into the C-terminal domain of KCTD12 and its interaction with cellular partners*
**作者**: Zhang R. et al.
**摘要**: 利用X射线晶体学和KCTD12抗体标记技术，解析了KCTD12蛋白C端结构域的三维构象，并阐明其与下游蛋白的相互作用界面，为开发靶向KCTD12的分子工具提供结构基础。
---
注：以上文献为示例性内容，实际引用需以真实发表的论文为准。建议通过PubMed或Google Scholar以“KCTD12 antibody”为关键词检索最新研究。
The KCTD12 antibody is a research tool used to detect and study the potassium channel tetramerization domain-containing protein 12 (KCTD12), a member of the KCTD protein family. KCTD12. also known as PFET1 or POB1. is involved in modulating G-protein-coupled receptor (GPCR) signaling, particularly through its interaction with the GABAB receptor. It regulates receptor desensitization and trafficking, impacting synaptic transmission and neuronal excitability. Dysregulation of KCTD12 has been implicated in neurological disorders, such as epilepsy, and certain cancers.
The antibody is typically developed in hosts like rabbits or mice using immunogenic peptides or recombinant KCTD12 protein. It is widely utilized in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and interactions in tissues or cell lines. Validation often includes knockout controls to confirm specificity. Researchers employ this antibody to explore KCTD12's role in cellular processes, disease mechanisms, and its potential as a therapeutic target. Its applications span neuroscience, oncology, and molecular biology, aiding in the understanding of GPCR signaling dynamics and pathophysiological pathways.
×
